Arkolith/Insider Trading/BCAX/Form 4

Mazumdar Claire

Chief Executive Officer, DirectorBicara Therapeutics Inc. (BCAX) · full profile →Form 4 · filed Mar 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$154K
Net Open-Market Flow
-$154K
Transactions
9
6 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 6, 2026Option exercise(M)4K$3.79$14K343K
Mar 6, 2026Sell(S)4K$18.75$72K339K
Mar 5, 2026Option exercise(M)2K$3.79$7K341K
Mar 5, 2026Sell(S)2K$18.74$33K339K
Mar 4, 2026Option exercise(M)3K$3.79$10K342K
Mar 4, 2026Sell(S)3K$18.73$49K339K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 6, 2026Option exercise(M)4K—$0228K
Mar 5, 2026Option exercise(M)2K—$0232K
Mar 4, 2026Option exercise(M)3K—$0233K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-015778) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML